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ABSTRACT
Proteases have been used in medicine for
several decades and are an established and
well tolerated class of therapeutic agent. These
proteases were sourced from mammals or
bacteria that exist or have adapted to
moderate temperatures (mesophilic
organisms); however, proteases derived from
organisms from cold environments—cold-
adapted or psychrophilic proteases—generally
have high specific activity, low substrate
affinity, and high catalytic rates at low and
moderate temperatures. Made possible by
greater flexibility, psychrophilic enzymes
interact with and transform the substrate at
lower energy costs. Cold-adapted proteases
have been used in a wide range of
applications, including industrial functions,
textiles, cleaning/hygiene products, molecular
biology, environmental bioremediations,
consumer food products, cosmetics, and
pharmaceutical production. In addition to
these applications, they have also shown
promise as therapeutic modalities for
cosmeceutical applications (by reducing
glabellar [frown] lines) and a number of
disease conditions, including bacterial
infections (by disrupting biofilms to prevent
bacterial infection), topical wound
management (when used as a debridement
agent to remove necrotic tissue and fibrin
clots), oral/dental health management (by
removing plaque and preventing periodontal
disease), and in viral infections (by reducing
the infectivity of viruses, such as human
rhinovirus 16 and herpes simplex virus).
Psychrophilic proteases with greater activity
and stability (than the original organism-
derived variant) have been developed; this
coupled with available manufacturing
recombinant production techniques suggests
that cold-adapted proteases have a promising
future as a distinct therapeutic class with
diverse clinical applications.
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Enzymes that cleave peptide bonds in proteins
are also known as proteases, proteinases,
peptidases, or proteolytic enzymes [1], and
function to accelerate the rate of specific
biologic reactions by lowering the activation
energy of the reaction [2]. Proteases are most
often assumed only to be involved in processes
relating to digestion, but the fact that over 2%
of the human genome encodes protease genes
suggests that they play more complex functions
than digestion alone [3]. Indeed, proteases have
been shown to be involved in the regulation of
a number of cellular components from growth
factors to receptors, as well as processes
including immunity, complement cascades,
and blood coagulation [3]. In addition to
involvement in homeostatic processes,
increased or dysregulated activity of proteases
has been implicated in cancer via its link with
tumor growth and invasion [4].
Briefly, proteases are initially produced as
inactive precursors, or zymogens, and are
distributed in specific organs or locations,
where they have little catalytic ability until
they are activated by proteolytic cleavage [5].
Further posttranslational mechanisms to
control the activity of proteases include
phosphorylation, cofactor binding, and
segregation of enzyme and/or substrate in
vesicles or granules. In addition, the effective
concentration of active enzyme can also be
strictly regulated by protease inhibitors, which
can reduce functional efficacy by forming a
complex with the protease and effectively
‘‘balance’’ proteolytic activity [6]. In this short
review, the therapeutic uses and future outlook
for proteases (notably cold-adapted proteases)
will be discussed.
THERAPEUTIC USE OF PROTEASES
Proteases have been used in medicine for several
decades and are an established and well
tolerated class of therapeutic agent [3]. Early
documented use of proteases in the published
literature appeared over 100 years ago [7–9].
In general, proteases have been used
therapeutically in four areas: the management
of gastrointestinal disorders with orally
administered agents, as anti-inflammatory
agents, as thrombolytic agents for
thromboembolic disorders, and as locally
administered agents for wound debridement
[10]. Since the first approval of a protease drug
in 1978 (urokinase, a serine protease indicated
for thrombolysis and catheter clearing), a
further 11 drugs have been approved for
therapeutic use by the US Food and Drug
Administration (FDA) [3]. The majority of
these are indicated for the treatment of blood
disorders and include thrombolytics: alteplase,
reteplase, and tenecteplase; and procoagulants:
factor IX, factor VIIa, thrombin, and topical
thrombin in bandages. The other approved
protease therapeutics are indicated for
digestion (pancrelipase), muscle spasms, and as
cosmeceuticals (cosmetic products with
biologically active ingredients intended to
have medicinal or drug-like benefits;
botulinum toxin A and botulinum toxin B) [3].
The use of topical proteases as a tool for
selective tissue destruction (i.e., ablation of
diseased tissue to expedite improvement or
cure) is an attractive one. Epidermally
confined dermatologic disorders, i.e., those for
16 Infect Dis Ther (2013) 2:15–26
123
which the primary disease is confined to the
epidermis (e.g., verruca or actinic keratosis), are
known to be cured using superficial destructive
techniques to remove diseased skin, allowing
the regeneration of healthy tissue from
adjacent/accessory structures [2]. Precise tissue
destruction is also a desirable property and is
possible with topically administered proteases.
For example, the ideal method to destroy an
epidermal neoplasm would involve selective
elimination of malignant tissue without
causing damage to healthy tissue or deeper
structures. Therefore, exploiting the unique
ability of proteases to cause selective epidermal
separation is an attractive approach to achieve
such desired precision. However, such a level of
precision is currently not achievable using
conventional methods of therapeutic tissue
destruction, such as cryosurgery (with liquid
nitrogen), electrosurgery, laser surgery,
chemosurgery, and cold-steel surgery, which
can produce tissue damage (to varying degrees)
that extend unnecessarily beyond the
epidermis, which can result in delayed
healing, scar formation, and alterations to
pigmentation [2]. As a consequence, there has
been great interest in using the selective
properties of enzymes and, thus, proteases
have been examined for effectiveness in a
number of such topical applications, including
animal models of acne vulgaris, wound healing,
epidermal ablation, and debridement of
necrotic ulcers.
Trypsin demonstrated antiaging properties
and a comedolytic effect (i.e., opening up of
clogged pores and lysis of comedones [hard
plugs of keratin and sebum within hair
follicles]) in a murine model of acne [11]. The
principle physiological change that leads to
acne vulgaris is the process of a sebaceous
follicle transforming to a comedone via hyper-
cornification and hyper-keratinization of the
infundibulum (i.e., the funnel in which the hair
follicle grows). A murine model was used to
quantify the effects of daily topical trypsin over
5 days’ treatment and resulted in improved skin
plasticity, increased cell layers in the dermis and
epidermis, as well as increased skin elasticity
when compared with control treatment. In
addition, when compared with controls,
trypsin induced follicular-epidermal
differentiation and also prevented extensive
programmed cell death and apoptosis [11].
Collagenase ointment has also shown
benefits in wound healing by achieving
selective debridement in porcine models [12].
Partial or full-thickness wounds in Yorkshire
pigs were contaminated with Staphylococcus
aureus and Pseudomonas aeruginosa, then
treated with Clostridium collagenase ointment
(Santyl; Healthpoint Ltd., Fort Worth, Texas,
USA), or controls of white petrolatum or moist
dressing and untreated wounds. Following
treatment over 8 days, collagenase ointment
achieved complete re-epithelialization in 85%
of animals with partial-thickness wounds
compared with only 10% using petrolatum
and 0% using moist dressing and untreated
wounds. Furthermore, significantly less
inflammation and less neutrophil infiltration
was observed by histology in the animals
treated with collagenase, and re-
epithelialization was enhanced, compared
with petrolatum [12].
The potential of topically applied proteases
for epidermal ablation has also been
demonstrated through the in vitro and in vivo
use of subtilisin, trypsin, and dispase in murine
and human skin samples. These proteases target
keratin, desmosomes, and collagen IV,
respectively. Following application, they
all demonstrated subcorneal separation,
intraepidermal acantholysis, and subepidermal
dissociation [2]. Furthermore, topical
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application of a 2.5% (w/v) solution of bovine
trypsin to two seborrheic keratosis for 15 min
on the trunk of a human participant destroyed
the lesions after 1 month, and after 3 months
there was no evidence of scarring, pigment
changes, or residual seborrhoea keratosis [2].
The use of streptokinase-streptodomase or
crystalline trypsin (Trypure; Novo Nordisk,
Bagsvaerd, Denmark) impregnated in wound
dressings was examined in patients with
necrotic varicose or arteriosclerotic leg ulcers.
Treatment with either protease resulted in a
significant reduction in pus and debris
associated with the ulcers, as well as a
significant increase in tissue granulation
(P\0.01 in both groups). Compared with
trypsin, the streptokinase-streptodomase
formulation was associated with less pain
(P\0.01) [13].
In the face of increasing antibiotic resistance
among bacteria, development of therapeutics
has broadened to compounds that target
virulence factors rather than viability.
Antivirulence strategies would be less likely to
result in the emergence of mutations leading to
resistance, due to the reduced impact on the
level of selective pressure on the bacterial
population [14]. A virulence factor recognized
as a tremendous burden on our healthcare
system is the formation of bacteria into
biofilm. Biofilms, complex structures
notoriously difficult to disassemble, protect
the colonizing bacteria from the host’s
immune system and from antibiotic therapy.
Much research effort to develop new
prophylactic and therapeutic agents has
focused on the inhibition of biofilm formation
or dispersal of established biofilms, as this
would release the bacteria into their
planktonic phenotype, which is much more
sensitive to antibiotics and to the immune
defenses [14].
Efforts to discover effective antibiofilm
therapeutic alternatives to antibiotics have
been plentiful, and much of that effort has
focused on enzyme-based treatments. For
example, proteinase K and trypsin were shown
to be effective in disrupting biofilm formed
by certain staphylococcal strains [15]. The
overexpression of bacterial extracellular
proteases inhibited biofilm formation [16], and




The proteases so far approved by the US FDA are
sourced from a range of mammals or bacteria
that exist or have adapted to moderate
temperatures—i.e., mesophilic organisms. In
the pursuit of more effective and more flexible
proteases, the therapeutic potential of
molecules derived from organisms from cold
environments has been examined. Those
organisms from the three domains of life
(bacteria, archaea, eucarya) that thrive in cold
environments (i.e., psychrophiles) have
developed enzymes that generally have high
specific activity, low substrate affinity, and high
catalytic rates at low and moderate
temperatures [18–20]. In general, when
compared with mesophilic variants, the
property of greater flexibility in psychrophilic
enzymes allows the protease to interact with
and transform the substrate at lower energy
costs. The comparative ease of interaction is
possible because the catalytic site of the
psychrophilic protease can accommodate the
substrate more easily [20]. However, this
increased flexibility is often accompanied by a
trade-off in stability [21]. Therefore, in contrast
to mammalian analogs, psychrophilic proteases
18 Infect Dis Ther (2013) 2:15–26
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are more sensitive to inactivation by heat, low
pH, and autolysis [18, 19, 21–25].
Comparisons between psychrophilic and
mesophilic trypsins suggested that there are a
number of structural features that are unique to
the cold-adapted trypsins that give greater
efficiency, but also reduced stability. Their
greater efficiency and catalytic ability arise
because of deletions from the surrounding
loop regions of the structure. This increased
flexibility is generally most pronounced around
the site of catalytic activity and enables the
protease to move and facilitate reactions at low
temperatures, and in a low energy environment
[26]. The increased catalytic activity is thought
to result from optimization of the electrostatic
forces (hydrogen bonds, van der Waals
interactions, and ion pairs) at the active site
[27]; for cold-adapted serine proteases, this is
thought to result from the lower electrostatic
potential of the S1 binding pocket caused by the
lack of hydrogen bonds adjacent to the catalytic
triad [25].
Catalytic activity or enzyme efficiency is
often expressed as kcat/KM (i.e., the specificity
constant), where kcat represents the catalytic
production of a product under ideal conditions
(i.e., turnover number) and KM represents the
Michaelis constant or the affinity of the
protease for the substrate. Generally, the high
catalytic rates observed in cold-adapted
proteases are the result of modifications in
enthalpy favoring higher turnover numbers.
However, when looking at proteases that have
adapted through strong KM improvement, such
as trypsin (that does not only increase kcat but
also increases its catalytic efficiency by lowering
its KM), the distinction between these
mesophilic and psychrophilic proteases
become more pronounced. An example of this
is seen by a 17 times greater catalytic efficiency
with trypsin from Atlantic cod, compared with
trypsin from bovine sources (Fig. 1) [22].
Detailed examination of the temperature
performance of cod and bovine trypsin
demonstrated that the cod-derived protease
displayed a twofold increase in kcat and a more
than eightfold improvement (reduction) in KM.
Practically, the main implication of a lower KM
is that a lesser amount of enzyme is required to
gain a high catalytic efficiency. Furthermore, in
a study comparing Atlantic cod trypsin with
Fig. 1 Example of the large impact of temperature on the
speciﬁcity constant kcat/KM on a cold-adapted protease,
here determined for Atlantic cod trypsin and its mesophilic
homolog, bovine trypsin, using the synthetic substrate,
benzoyl-L-arginine p-nitroanilide. The same pattern also
applies to other substrates. kcat turnover number, KM
Michaelis constant. Adapted with permission from
Asgeirsson et al. [22]
Infect Dis Ther (2013) 2:15–26 19
123
bovine trypsin [28], the cod trypsin cleaved
proteins more effectively across a range of
temperatures. For example, at temperatures up
to 25C, cod trypsin more effectively cleaved
intercellular adhesion molecule 1, myoglobin,
lactoferrin, and lysozyme when compared with
bovine trypsin. At lower temperatures (4C),
this difference in effect was even more
pronounced. Overall, it appears that for cold-
adapted proteases, the enzyme activity curve as
a function of temperature is shifted toward low
temperature (compared with their mesophile
counterparts). Therefore, either due to
improved kcat or KM, the catalytic activity
(kcat/KM) values are higher for psychrophilic
proteases than their mesophilic counterpart
over a temperature range from 0C to at least
30C. In fact, many cold-adapted enzymes have
temperature optima in the range of, or even
closer to, the temperature range in which
mesophilic enzymes operate naturally, than
mesophilic enzymes themselves [18, 22].
However, the greater efficacy is accompanied
by a reduced thermal stability, evident in the
fast denaturation at moderate temperatures
[18, 27]. Variations in the flexibility and
rigidity of the psychrophilic protein may
explain the greater adaptability and efficacy at
lower temperatures, and also the reduced
stability. Structural changes, such as fewer
hydrogen bonds, fewer salt bridges, and poorer
van der Waals packing interactions in the core,
are evident in psychrophilic proteases [25].
However, this is not a widespread rule; while
some psychrophilic proteases have lower
stability than mesophilic analogs, some have
decreased stability only at the sites of substrate
binding and catalysis [10, 29].
Clearly, if a psychrophilic protease were to be
the most effective in a mesophilic environment,
there is the obvious requirement to enhance its
fundamental stability and functionality. Before
applying the thermal stability traits of a
mesophilic protease to a psychrophilic analog,
an understanding of the relationship between
stability, static and dynamic flexibility or
plasticity, and catalytic efficiency of cold-
adapted proteases is required. Site-directed
mutagenesis and directed evolution are among
the methods expected to produce proteases that
exhibit the stability of a mesophilic product
while retaining the efficiency of a psychrophilic
molecule [21, 30–33].
Using random mutagenesis, saturation
mutagenesis, and in vitro recombination/DNA
shuffling, Miyazaki and colleagues [31]
generated mutant libraries of the psychrophilic
protease, subtilisin S41. Of the resulting
proteases, one variant (3-2G7) had an optimal
operating temperature increased by 10C,
without compromising activity at low
temperatures, and exhibited threefold greater
catalytic efficiency. Subsequent generations of
this protease have also been developed and
have demonstrated even greater levels of
activity and stability [32]. One of the authors
postulated that a protease with increased
activity at low temperature and stability at
higher temperatures can exist physically, but it
had not been found naturally due to the course
of evolution [31].
While it has been shown that it is possible to
modify psychrophilic proteases to be more
stable at higher temperatures, the opposite is
also true: existing mesophilic proteases can be
engineered to achieve improved function at low
temperatures. For example, based on subtilisin
BPN’, an alkaline serine protease, sequential
in vitro mutagenesis was employed to produce a
cold-adapted mutant. Using three mutations in
the structure of subtilisin, two that enhanced
activity and one that reduced activity, a
cold-adapted variant was produced that had a
100% increase in activity compared with the
20 Infect Dis Ther (2013) 2:15–26
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wild type. The increase in activity was primarily
attributed to increased affinity of the mutant
variant for the substrate [33].
That the cold-adapted proteases exhibit
reduced stability at moderate temperatures
need not be considered a disadvantage; in fact,
it could prove to be an important property for
exploitation if considered for therapeutic use, in
particular, topical administration. Therefore,
while psychrophilic proteases have high
activity and efficiency when applied locally at
ambient temperatures, because they are
optimized for activity at lower temperatures,
they will lose activity and be degraded once
equilibrium with the warmer in vivo
environment is reached; thereby limiting the
duration of activity and ensuring that the
protease only exhibits a controlled localized
effect. Another factor favoring cold-adapted
proteases with regard to safety in therapeutic
use is that the high catalytic efficiency requires
exposure to a smaller amount of enzyme. This is
particularly true for proteases with a low KM,
such as cod trypsin. Furthermore, the inherent
greater flexibility of cold-adapted proteases has
been reported to be particularly useful in
conditions, such as low water conditions (e.g.,
targeting lipid membrane proteins, lipid layer of
mucus), wherein the activity of mesophilic and
thermophilic enzymes is severely impaired by
the high level of structural rigidity [34].
In the event that an extended half-life or
greater exposure may be required, proteases can
be administered in their inactive zymogen form
(to be subsequently activated in vivo).
Furthermore, greater tolerability may be
achieved by engineering the protease to have
reduced antigenicity and immunogenicity [35].
While psychrophilic proteases have been
obtained from biological sources, such as
Atlantic cod (Gadus morhua) or Antarctic krill
(Euphausia superba), the large-scale production
of suitable quantities of homogenous cold-
adapted proteases could be obtained using
recombinant technologies. A wide variety of
fish enzymes and proteases has already been
identified, cloned, and expressed in
microorganisms [36]. In the production of
other proteases for therapeutic purposes, non-
human sources or production hosts are
preferred so that the potential for
contamination can be avoided. Recombinant
technologies are thus widely employed to
produce approved mammalian (recombinant)
therapeutic proteins, such as blood clotting
factors (from recombinant Chinese hamster
ovary or baby hamster kidney cells),
thrombolytics (from Escherichia coli), or
botulinum toxin (Clostridium botulinum) [3].
Therefore, it would appear logical to explore
the possibility of producing cold-adapted
proteases through recombinant technology.
There have been several, more or less
successful, attempts to do this in the
laboratory. However, large-scale production
of recombinant cold-adapted enzymes is
associated with several complicating factors,
such as the short half-life and autolytic
activity of cold-adapted enzymes, which makes
production difficult under more standardized
industrial conditions and temperatures.
THE USE OF COLD-ADAPTED
PROTEASES AS THERAPEUTICS
To date, cold-adapted proteases have been used
in a wide range of applications, including
industrial functions, textiles, cleaning/hygiene
products (detergents), molecular biology,
environmental bioremediations (reducing
contamination), consumer food products
(dairy manufacturing and preparation),
cosmetics, and pharmaceuticals (as biocatalysis
Infect Dis Ther (2013) 2:15–26 21
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in organic synthesis of drugs and/or
intermediates in their generation) [1, 10, 29].
Cosmeceuticals and Dermatology
The use of proteases for cosmeceuticals is of
great interest and potential. One example of
such a protease is the FDA-approved botulinum
toxin A indicated for muscle spasms. Botulinum
toxin A disrupts neurotransmission by
inhibiting acetylcholine release and inactivates
soluble N-ethylmaleimide-sensitive factor-
attachment protein 25 (SNAP-25). Although
indicated for the treatment of muscle spasms,
botulinum toxins are probably best known for
their utility in reducing glabellar (frown)
lines [3].
The removal of necrotic tissue and fibrin
clots is considered a critical phase in wound
care and, as such, proteases are considered to
have the potential to be important in the
removal of barriers to tissue regeneration and
tissue healing [37]. Investigations have shown
that proteolytic enzymes from Antarctic
krill (acidic endopeptidases [trypsin and
chymotrypsin-like enzymes] and exopeptidases
[carboxypeptidase A and B]) were shown to be
superior to saline control in facilitating recovery
in a standard porcine model of wound
management [38]. Electrokeratome and
trichloracetic acid were used to create necrotic
ulcers in a model of wound recovery in
domestic pigs, which were then treated twice
daily with dressings impregnated with various
concentrations of krill or saline control for
7 days. The krill proteases (at a concentration
of C3.0 casein units/mL) were found to be an
effective debridement tool that, when
compared with the control treatment,
significantly reduced the degree of necrotic
tissue (P\0.05), improved tissue granulation,
and enhanced wound healing [38]. In addition,
the krill proteases achieved wound cleaning
3–4 days earlier when compared with control
treatment.
Periodontal Disease
Tooth decay or dental cavities are caused by the
build-up of bacterial plaque and can lead to oral
disease. Formed through a number of steps
whereby ‘‘pioneer’’ bacteria adhere to dental
pellicle (the protein film on the surface of tooth
enamel) and subsequent bacteria adhere to the
pioneer colonizers, a matrix is formed of
salivary components and bacteria. If not
adequately managed by mechanical removal
(e.g., by brushing or flossing), the toxic bacterial
products from accumulated plaque can lead to
gingivitis and periodontal disease, the most
common oral disorder in industrialized
populations [39, 40]. Preventive measures to
reduce periodontal disease and the requirement
for dental treatments would have obvious
benefits.
Krill-derived proteases have shown potential
in the management of periodontal disease [41].
In vitro examination indicated that krill
enzymes were able to inhibit the binding of
oral bacteria to saliva-covered surfaces and
detach bacterial plaque; accumulated plaque
was effectively removed from dentures without
having an effect on the normal (beneficial)
microbial flora of the oral environment [39].
Furthermore, when used in a chewing gum
formulation, krill proteases were shown to
reduce gingivitis. In addition to regular dental
care, krill proteases (0.06 or 6.0 U) were
delivered via a chewing gum (for 10 min, four
times a day for 10 days) to healthy volunteers.
Compared with placebo gum, the krill protease-
containing gum disrupted bacterial adherence
to dental pellicle and a significant reduction
(54%, P\0.05) in gingival bleeding was seen
22 Infect Dis Ther (2013) 2:15–26
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with a therapeutic dose of 0.06 U krill enzymes
compared with placebo chewing gum [41]. The
gum containing proteolytic enzymes was found
to be well tolerated as none of the subjects
reported any adverse reactions or events during
the entire trial period.
Viral Infections
Acute nasopharyngitis, or the common cold,
caused by any one of a large number of
antigenically distinct viruses and as one of the
most common infectious syndromes in
humans, is associated with significant health
burden, both in terms of financial and quality of
life outcomes [42, 43]. Pathogens of the
enterovirus family (human rhinoviruses and
Coxsackie A virus serotypes) are the principal
causative agent in viral infections and can result
in symptoms such as sore throat, sneezing and
rhinorrhea, and secondary bacterial infections,
as well as more severe symptoms by
exacerbating asthma, chronic obstructive
pulmonary disease, and cystic fibrosis [42, 43].
Rhinovirus, the most common cause of colds
and acute respiratory tract illness [34], gains
entry into host cells of the nose and throat by
interacting with the human intercellular
adhesion molecule 1 (or CD54) [15]. This
suggests that proteases that target these
molecules, such as those from cod trypsin [28],
may have therapeutic potential in the
management of viral infections. Indeed,
in vitro studies have shown that exposing
viruses to trypsins results in a reduction in
infectivity/activation [44, 45]. Furthermore,
data from postmarket studies suggest that the
use of ColdZyme (Enzymatica AB, Lund,
Sweden) mouth spray, an oral solution
containing glycerol and a cold-adapted cod
trypsin, can reduce the incidence of the
common cold [46]. Marketed for use as a
moisturizer and to improve oral hygiene, users
of ColdZyme noted a reduced occurrence of
cold symptoms. The ColdZyme mouth spray
creates a thin film in the mouth and throat
cavity that acts as an active surface barrier with
proteolytic activity. Furthermore, the cold-
adapted trypsin used in ColdZyme mouth
spray has shown high efficiency in reducing
the infectivity of human rhinovirus 16 [46] and
herpes simplex virus 1 in vitro [47].
A summary of the proteases can be found in
Table 1 [2, 3, 11–13, 38, 39, 41, 46, 47].
CONCLUSION AND FUTURE
SCENARIOS
Proteases, a recognized, effective, and well
tolerated drug class that have been used
therapeutically over a number of years,
illustrate great potential in the management of
a number of disease conditions. This
recognition is a stimulus for the investigation
of promising proteolytic enzyme variants,
including cold-adapted proteases (and other
enzymes), for further therapeutic applications.
Cold-adapted proteases, therefore, have a
promising future as a distinct therapeutic class
with diverse clinical applications. This is
illustrated by their ability to catalyze biological
processes more effectively than mesophilic
analogs at lower temperatures, demonstrate
good safety profiles, have efficacy in topical
applications with a relatively localized effect,
and be readily manufactured through
recombinant production processes.
As our understanding of their structure and
function has broadened, proteases with greater
efficacy and stability have been produced while
retaining high specificity constants, which
provides a tantalizing insight into how they
might be employed as therapeutics in the
Infect Dis Ther (2013) 2:15–26 23
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future. Applications in which proteases may
hold promise in the future include the
prevention of infection and disease, enhancing
the management of peripheral artery disease
and thrombosis, dermatology, and wound care.
It is imperative that we continue
investigating ways in which potent candidates
such as cold-adapted proteases can offer
competent alternatives to traditional
pharmaceutical therapy, in particular when
systemically active agents, such as antibiotics,
are used to treat local bacterial or viral
infections. Therefore, the authors strongly
propose the consideration of cold-adapted
proteases as an emerging class of therapeutics
for the treatment of infectious diseases.
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Table 1 A summary of proteases for therapeutic use [2, 3, 11–13, 38, 39, 41, 46, 47]
FDA approved Use Protease description
Cardiovascular/hematology Thrombolytics Serine proteases urokinase; alteplase, reteplase, and tenecteplase
Procoagulants Factor IX, factor VIIa, thrombin, and topical thrombin in bandages
Dermatology Wound healing Collagenase
Digestion Digestion aid Pancrelipase
Neuromuscular Muscle spasms Botulinum toxin A and botulinum toxin B
Other Protease action/effect Protease
Dermatology Anti-aging properties and comedolytic effect Trypsin
Epidermal ablation Subtilisin, trypsin, and dispase
Wound healing Streptokinase-streptodomase
Wound debridement and management Acidic endopeptidases
(trypsin and chymotrypsin-like enzymes)
and exopeptidases (carboxypeptidase A and B)a
Periodontal disease Reducing plaque and gingivitis Acidic endopeptidases
(trypsin and chymotrypsin-like enzymes)
and exopeptidases (carboxypeptidase A and B)a
Infection Prevent contracting a cold (rhinovirus) Cod trypsin
Bioﬁlm disruption/antibacterial Proteinase K and trypsin
FDA US Food and Drug Administration
a From Arctic krill
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